[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Tag: Specialized Drugs/Medications
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
You Can Now Get Weight-Loss Drugs Right From Eli Lilly
[ad_1] Eli Lilly started a new online service offering telehealth prescriptions and direct home delivery of its new anti-obesity drug Zepbound, an unusual move into the drug supply chain by…
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
[ad_1] Updated Dec. 26, 2023 12:33 pm ET Drug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio…
AstraZeneca to Buy Icosavax for Up to $1.1 Bln
[ad_1] AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to $1.1 billion in a deal that expands its vaccines and immune therapies late-stage pipeline. The pharmaceutical…
The Forgotten Man of mRNA Research
[ad_1] Jason Schrum’s work helped lay the foundation for Moderna’s mRNA Covid vaccine, but he hasn’t won any prizes or royalties and left the company after disagreements. [ad_2] Source link
Merck MS Drug Fails to Meet Target of Late-Stage Trials
[ad_1] Merck’s multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials. The German pharmaceutical company’s phase 3 clinical trials for the drug did not achieve their primary…
Pfizer Warns 2024 Revenue Could Fall, Weighed Down by Soft Demand for Covid Products
[ad_1] Updated Dec. 13, 2023 10:16 am ET Pfizer shares tumbled Wednesday morning after the company said revenue could fall next year and issued 2024 guidance below analyst expectations. Shares…